Terrie Curran
Chief Executive Officer at PHATHOM PHARMACEUTICALS, INC.
Net worth: 4 M $ as of 2024-03-30
Profile
Terrie Curran is currently the President, Chief Executive Officer & Director at Phathom Pharmaceuticals, Inc. and a Director at Roivant Sciences, Inc. and an Independent Director at Arcutis Biotherapeutics, Inc. Ms. Curran previously served as an Independent Director at H.
Lundbeck A from 2014 to 2017, a Director at BioNJ, Inc., an Independent Director at Myovant Sciences Ltd.
from 2016 to 2023, the President-Global Inflammation & Immunology at Celgene Corp.
from 2017 to 2019, and the SVP & GM-Global Women's Health at Merck & Co., Inc. from 2009 to 2013.
Ms. Curran also worked as a General Manager at Schering-Plough Corp.
from 2003 to 2007.
Ms. Curran obtained an undergraduate degree from the University of Technology Sydney.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-21 | 414,624 ( 0.71% ) | 4 M $ | 2024-03-30 | |
| 2023-05-30 | 8,687 ( 0.01% ) | 86 088 $ | 2024-03-30 |
Terrie Curran active positions
| Companies | Position | Start |
|---|---|---|
| PHATHOM PHARMACEUTICALS, INC. | Chief Executive Officer | 2019-12-01 |
| ARCUTIS BIOTHERAPEUTICS, INC. | Director/Board Member | 2020-11-01 |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Director/Board Member | - |
Former positions of Terrie Curran
| Companies | Position | End |
|---|---|---|
| MYOVANT SCIENCES LTD. | Director/Board Member | 2023-03-09 |
| CELGENE | Corporate Officer/Principal | 2019-08-31 |
| H. LUNDBECK A/S | Director/Board Member | 2017-02-28 |
| MERCK & CO., INC. | Corporate Officer/Principal | 2013-03-31 |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Corporate Officer/Principal | 2007-03-31 |
Training of Terrie Curran
| University of Technology Sydney | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| H. LUNDBECK A/S | Health Technology |
| ARCUTIS BIOTHERAPEUTICS, INC. | Health Technology |
| PHATHOM PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
BioNJ, Inc.
 BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services BioNJ, Inc. is based in Trenton, NJ. BioNJ, Inc. is a life sciences trade association with nearly 400 member companies. The company supports the discovery, development, and commercialization of therapies and cures that save and improve lives. BioNJ drives capital formation, fosters entrepreneurship, advocates for medical innovation, provides access to talent and education, and offers critical commercial resources. The company also serves as a clearinghouse for funding information and opportunities. The company was founded in 1994 by James J. Marino, Jayne C. Gershkowitz, Abraham Abuchowski. The CEO is Debbie Hart. | Commercial Services |
Myovant Sciences Ltd.
 Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Terrie Curran
